Benzinga | Sep 24, 2021 05:21AM EDT

Stifel Initiates Coverage On Intellia Therapeutics with Buy Rating, Announces Price Target of $173

Stifel analyst Dae Gon Ha initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Buy rating and announces Price Target of $173.